PMID- 29199164
OWN - NLM
STAT- MEDLINE
DCOM- 20180724
LR  - 20180724
IS  - 2148-5607 (Electronic)
IS  - 1300-4948 (Linking)
VI  - 28
IP  - Suppl 1
DP  - 2017 Dec
TI  - Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma 
      development in Barrett's esophagus?
PG  - S31-S32
LID - 10.5152/tjg.2017.09 [doi]
AB  - Besides reducing the reflux symptoms, the benefit of proton pump inhibitors (PPI) 
      in the treatment of Barrett's esophagus (BE) is not exactly known. The data in 
      the literature show that although the PPI treatment does not reduce the Barrett's 
      segment length, it can reduce dysplasia or the development of early-stage 
      adenocarcinoma (odds ratio (OR): 0.46). Therefore, treatments with PPI may be 
      considered in patients with a diagnosis of BE and at a high risk of 
      adenocarcinoma, even though they are not symptomatic.
FAU - Akin, Hakan
AU  - Akin H
FAU - Aydin, Yucel
AU  - Aydin Y
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Turkey
TA  - Turk J Gastroenterol
JT  - The Turkish journal of gastroenterology : the official journal of Turkish Society 
      of Gastroenterology
JID - 9515841
RN  - 0 (Proton Pump Inhibitors)
RN  - Adenocarcinoma Of Esophagus
SB  - IM
MH  - Adenocarcinoma/etiology/*prevention & control
MH  - Adult
MH  - Barrett Esophagus/complications/*drug therapy/pathology
MH  - Esophageal Neoplasms/etiology/*prevention & control
MH  - Esophagus/*pathology
MH  - Female
MH  - Humans
MH  - Hyperplasia/etiology/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Treatment Outcome
EDAT- 2017/12/05 06:00
MHDA- 2018/07/25 06:00
CRDT- 2017/12/05 06:00
PHST- 2017/12/05 06:00 [entrez]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2018/07/25 06:00 [medline]
AID - 10.5152/tjg.2017.09 [doi]
PST - ppublish
SO  - Turk J Gastroenterol. 2017 Dec;28(Suppl 1):S31-S32. doi: 10.5152/tjg.2017.09.